A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy — VALOR-HCM  

HOCM, Hypertrophic Obstructive Cardiomyopathy Clinical Trial

Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

Status Active, not recruiting

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multi-center study in the United States (U.S.) that will evaluate the effect of mavacamten treatment on reducing the number of septal reduction therapy (SRT) procedures performed in subjects with symptomatic obstructive hypertrophic cardiomyopathy (oHCM [also known as HOCM]) who are eligible for SRT based on ACCF/AHA 2011 and/or ESC 2014 guidelines.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cardiomyopathies
• Cardiomyopathy, Hypertrophic
• HOCM, Hypertrophic Obstructive Cardiomyopathy
• Hypertrophy

• NCT number: NCT04349072
• Study type: Interventional
• Source: Bristol-Myers Squibb
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: July 6, 2020
• Completion date: June 11, 2024